drugset / Trial / NCT05490264
[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors
Phase 0
Unknown
20 enrolled
SmartNuclide Biopharma
The First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to evaluate the safety of \[68Ga\]Ga-NOTA-SNA002 and investigate the uptake of \[68Ga\]Ga-NOTA-SNA002 in patients with solid tumors.
Timeline
- Start
- 2022-10-18
- Primary completion
- 2024-06-30
- Completion
- 2024-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [68Ga]Ga-NOTA-SNA002 | Diagnostic / imaging agent | 0.1 mg | Intravenous |
| Subject | [68Ga]Ga-NOTA-SNA002 | Diagnostic / imaging agent | 0.9 mg | Intravenous |
| Subject | [68Ga]Ga-NOTA-SNA002 | Diagnostic / imaging agent | 1 unknown | Intravenous |
| Subject | [68Ga]Ga-NOTA-SNA002 | Diagnostic / imaging agent | 5 unknown | Intravenous |